Bisphosphonates and bone metastases;Bisphosphonates et metastases osseuses

Bulletin du Cancer

Volumn 86, Issue 9, 1999, Pages 732-738

  Lortholary, Alain ^a   Jadaud, Éric ^a   Berthaud, Patrice ^b  

^a CENTRE PAUL PAPIN   (France)

^b NOVARTIS PHARMA K K   (Japan)

Author keywords

Bisphosphonates; Bone metastases; Pain

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; IBANDRONIC ACID; INCADRONIC ACID; OLPADRONIC ACID; PACLITAXEL; PAMIDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT;

BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENTIATION; EYE TOXICITY; FEVER; HUMAN; HYPERCALCEMIA; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTOPENIA; MULTIPLE MYELOMA; MYALGIA; ORAL DRUG ADMINISTRATION; PROSTATE CANCER; REVIEW; BONE DISEASE; BONE TUMOR; BREAST TUMOR; CONTROLLED CLINICAL TRIAL; MALE; METASTASIS; PAIN; PATHOLOGY; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC AGENTS; BONE DISEASES; BONE NEOPLASMS; BREAST NEOPLASMS; CLODRONIC ACID; DIPHOSPHONATES; HUMANS; HYPERCALCEMIA; MALE; MULTIPLE MYELOMA; PAIN; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS;

EID: 0033193075     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. 1. Nielsen OS. Palliative treatment of bone metastases. Acta Oncol Suppl 1996 ; 35 : 58-60.
2. 2.Tubiana-Hulin M. Traitements médicaux des métastases osseuses. Bull Cancer 1996 ; 83 : 299-304.
3. 3. Urwin GH, Percival RC, Harris S, et al. Generalised increase in bone resorption in carcinoma of the prostate. Br J Urol 1985 ; 57 : 721-3.
4. 4. Mundy GR, Yoneda T. Bisphosphonates as anticancer drugs. N Engl J Med 1998 ; 339 : 398-400.
5. 5. Fleisch H. Bisphosphonates : pharmacology and use in the treatment of tumor-induced hypercalcaemic and metastatic bone disease. Drugs 1991 ; 42 : 919-44.
6. 6. Harvey HA. The management of hypercalcemia of malignancy. Support Care Cancer 1995 ; 3 : 123-9.
7. 7. Lortholary A, Alleaume C, Pein F, Larra F. Métastases ostéolytiques du cancer du sein et bisphosphonates. Rev Med Interne 1992 ; 13 : 238-42.
8. 8. Body JJ. Clinical trials in metastatic breast cancer to bone : past, present, future. Can J Oncol 1995 ; 5 (suppl. 1) : 16-27.
9. 9. Elomaa I, Blomqvist C, Grohn P. Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet 1983 ; 1 : 146-9.
10. 10. Bloomfield DJ. Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers ? An evidence-based review. J Clin Oncol 1998 ; 16 : 1218-25.
11. 11. Belch AR, Bergsagel DE, Wilson K, et al. Effect of daily etldronate on the osteolysis of multiple myeloma. J Clin Oncol 1991 ; 9 : 1397-402.
12. 12. Lahtinen R, Laakso M, Palva I, et al. Randomised placebo controlled multicentre trial of clodronate in multiple myeloma. Lancet 1992 ; 340 : 1049-52.
13. 13. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996 ; 334 : 488-93.
14. 14. Berenson JR, Lichtenstein A, Porter L, et al. Long term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 1998 ; 16 : 593-602.
15. 15. McCloskey EV, MacLennan CM, Drayson MT, et al. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. Br J Haematol 1998 ; 100 : 317-25.
16. 16. Van Holten-Verzantvoort A, Kroon H, Bijvoet F. Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 1993 ; 11 : 491-8.
17. 17. Paterson A, Powles T, Kanis J, et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993 ; 11 : 59-65.
18. 18. Conte PF, Latreille L, Mauriac L, et al. Delay in progression of bone metastases in breast cancer treated with intravenous pamidronate : results from a multi-national controlled trial. J Clin Oncol 1996 ; 14 : 2552-9.
19. 19. Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and bone metastases. N Engl J Med 1996 ; 335 : 1785-91.
20. 20. Lipton A. Bisphosphonate and breast carcinoma. Cancer 1997 ; 80 (suppl. 8) : 1668-73.
21. 21. Van Holten-Verzantvoort A, Hermans J, Beex L. Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients ? Eur J Cancer 1996 ; 32A : 450-4.
22. 22. Kanis JA, Poxles TJ, Paterson AHG, et al. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 1996; 19 : 663-7.
23. 23. Diel IJ, Solomayer EF, Costa SD et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998 ; 339 : 357-63.
24. 24. Vorreuther R. Bisphosphonate as an adjunct to palliative therapy of bone metastases from prostatic carcinoma. A pilot study on clodronate. Br J Urol 1993 ; 72 : 792-5.
25. 25. Cresswell SM, English PJ, Hall RR, Roberts JT, Marsh MM. Pain relief and quality-of-life assessment following intravenous and oral clodronate in hormone-escaped metastatic prostate cancer. Br J Urol 1995 ; 76 : 360-5.
26. 26. Adami S. Bisphosphonates in prostate carcinoma. Cancer 1997 ; 80 (suppl. 8) : 1674-9.
27. 27. Pelger RC, Hamdy NA, Zwinderman AH, et al. Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton. Bone 1998 ; 22 : 403-8.
28. 28. Smith JA. Palliation of painful bone metastases from prostate cancer using sodium etidronate : results of a randomized, prospective, double-blind, placebo-controlled study. J Urol 1989 ; 141 : 85-7.
29. 29. Elomaa I, Kylmala T, Tammela T, et al. Effect of oral clodronate on bone pain. A controlled study in patients with metastatic prostatic cancer. Int Urol Nephrol 1992 ; 24 : 159-66.
30. 30. Kylmala T, Tammela T, Risteli L, et al. Evaluation of the effect of oral clodronate on skeletal metastases with type i collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group. Eur J Cancer 1993 ; 29a : 821-5.
31. 31. Strang P, Nilsson S, Brandstedt S, et al. The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer. Anticancer Res 1997 ; 17 : 4717-21.
32. 32. Kylmala T, Castren-Kortekangas P, Seppanen J, Ylitalo P, Tammela TL. Effect of concomitant administration of clodronate and estramustine phosphate on their bioavailability in patients with metastasized prostate cancer. Pharmacol Toxicol 1996 ; 79 : 157-60.
33. 33. Ernst Sd, MacDonald N, Paterson A, et al. A double blind crossover trial of intravenous clodronate in metasraric bone pain. J Pain Symptom Manage 1992 ; 7 : 4-11.
34. 34. Robertson AG, Reed NS, Ralston SH. Effect of oral clodronate on metastatic bone pain : a double blind, placebo controlled study. J Clin Oncol 1995 ; 13: 2427-30.
35. 35. Paterson AHG. Should bisphosphonates be standard therapy for bone pain ? Support Care Cancer 1997 ; 5 : 200-4.
36. 36. Fleisch H. Bisphosphonates, history and experimental basis. Bone 1987; 8 (suppl. 1) : 23-8.
37. 37. Ralston SH, Gallacher SJ, Patel U, et al. Comparison of three intravenous bisphosphonates in cancer associated hypercalcaemia. Lancet 1989 ; 2 : 1180-2.
38. 38. Purohit OP, Radstone CR, Anthony C, Kanis JA, Coleman RE. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. Br J Cancer 1995 ; 72 : 1289-93.
39. 39. Vinholes J, Guo CY, Purohit OP, Eastell R, Coleman RE. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronare for hypercalcaemia of malignancy. J Clin Oncol 1997; 15 : 131-8.
40. 40. Coleman RE, Purohit OP, Vinholes JJ, Zekri J. High dose pamidronate : clinical and biochemical effects in metastatic bone disease. Cancer 1997 ; 80 : 1686-90.
41. 41. Cascinu S, Graziano F, Alessandroni P, et al. Different doses of pamidronate in patients with painful osteolytic bone metastases. Support Care Cancer 1998 ; 6 : 139-43.
42. 42. Body JJ, Dumont JC, Piccart M, Ford J. Intravenous pamidronate in patients with tumor-induced osteolysis : a biochemical dose-response study. J Bone Miner Res 1995 ; 10 : 1191-6.
43. 43. Glover D, Lipron A, Keller A, et al. Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. Cancer 1994 ; 74: 2949-55.
44. 44. Pecherstorfer M, Ludwig H, Schlosser K, et al. Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection. J Bone Miner Res 1996 ; 11 : 587-93.
45. 45. Usui T, Tanaka S, Sonoda T, et al. Drug disposition of incadronate, a new bisphosphonate, in rats with bone metastases. Xenobiotica 1997 ; 27 : 479-87.
46. 46. Hiraga T, Tanaka S, Yamamoto M, Nakajima T, Ozawa H. Inhibitory effect if bisphosphonate (YM 175) on bone resorption induced by a metastatic bone tumor. Bone 1996 ; 18 : 1-7.
47. 47. Sasaki A, Boyce BF, Story B, et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in nude mice. Cancer Res 1993 ; 55: 3551-7.
48. 48. Body JJ. Clinical research update : zoledronate. Cancer 1997 ; 80 (suppl. 8) : 1699-701.
49. 49. Coleman RE. Management of bone metastases. In: Perry MC. Educational Book, Thirty-fourth annual meeting of American Society of Clinical Oncology. Los Angeles, 1998 ; 100-8.
50. 50. Body JJ, Lortholary A, Romieu G, Vigneron AM, Ford J. A dose-finding study of zoledronate in hypercalcemic cancer patients. J Bone Miner Res (soumis à publication).
51. 51. Stearms ME, Wang M. Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice. Invasion Metastasis 1996 ; 16 : 116-31.